63 related articles for article (PubMed ID: 37898816)
21. Epistatic Interactions Between Mutations of Deoxyribonuclease 1-Like 3 and the Inhibitory Fc Gamma Receptor IIB Result in Very Early and Massive Autoantibodies Against Double-Stranded DNA.
Weisenburger T; von Neubeck B; Schneider A; Ebert N; Schreyer D; Acs A; Winkler TH
Front Immunol; 2018; 9():1551. PubMed ID: 30026744
[TBL] [Abstract][Full Text] [Related]
22. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
[TBL] [Abstract][Full Text] [Related]
23. The role of monogamous bivalency and Fc interactions in the binding of anti-DNA antibodies to DNA antigen.
Stearns NA; Pisetsky DS
Clin Immunol; 2016 May; 166-167():38-47. PubMed ID: 27083935
[TBL] [Abstract][Full Text] [Related]
24. Topoisomerase I alone is sufficient to produce short DNA deletions and can also reverse nicks at ribonucleotide sites.
Huang SY; Ghosh S; Pommier Y
J Biol Chem; 2015 May; 290(22):14068-76. PubMed ID: 25887397
[TBL] [Abstract][Full Text] [Related]
25. The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis.
Keil A; Frese-Schaper M; Steiner SK; Körner M; Schmid RA; Frese S
Arthritis Rheumatol; 2015 Jul; 67(7):1858-67. PubMed ID: 25779651
[TBL] [Abstract][Full Text] [Related]
26. Low-dose irinotecan improves advanced lupus nephritis in mice potentially by changing DNA relaxation and anti-double-stranded DNA binding.
Frese-Schaper M; Keil A; Steiner SK; Gugger M; Körner M; Kocher GJ; Schiffer L; Anders HJ; Huynh-Do U; Schmid RA; Frese S
Arthritis Rheumatol; 2014 Aug; 66(8):2259-69. PubMed ID: 24729466
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.
Mysler EF; Spindler AJ; Guzman R; Bijl M; Jayne D; Furie RA; Houssiau FA; Drappa J; Close D; Maciuca R; Rao K; Shahdad S; Brunetta P
Arthritis Rheum; 2013 Sep; 65(9):2368-79. PubMed ID: 23740801
[TBL] [Abstract][Full Text] [Related]
28. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.
Hahn BH; McMahon MA; Wilkinson A; Wallace WD; Daikh DI; Fitzgerald JD; Karpouzas GA; Merrill JT; Wallace DJ; Yazdany J; Ramsey-Goldman R; Singh K; Khalighi M; Choi SI; Gogia M; Kafaja S; Kamgar M; Lau C; Martin WJ; Parikh S; Peng J; Rastogi A; Chen W; Grossman JM;
Arthritis Care Res (Hoboken); 2012 Jun; 64(6):797-808. PubMed ID: 22556106
[No Abstract] [Full Text] [Related]
29. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
Rovin BH; Furie R; Latinis K; Looney RJ; Fervenza FC; Sanchez-Guerrero J; Maciuca R; Zhang D; Garg JP; Brunetta P; Appel G;
Arthritis Rheum; 2012 Apr; 64(4):1215-26. PubMed ID: 22231479
[TBL] [Abstract][Full Text] [Related]
30. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA;
Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403
[TBL] [Abstract][Full Text] [Related]
32. Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan.
Frese-Schaper M; Zbaeren J; Gugger M; Monestier M; Frese S
J Immunol; 2010 Feb; 184(4):2175-82. PubMed ID: 20083657
[TBL] [Abstract][Full Text] [Related]
33. What have we learned about optimal induction therapy for lupus nephritis (III through V) from randomized, controlled trials?
Clark WF; Sontrop JM
Clin J Am Soc Nephrol; 2008 May; 3(3):895-8. PubMed ID: 18287258
[No Abstract] [Full Text] [Related]
34. Human DNA topoisomerase I: relaxation, roles, and damage control.
Leppard JB; Champoux JJ
Chromosoma; 2005 Jul; 114(2):75-85. PubMed ID: 15830206
[TBL] [Abstract][Full Text] [Related]
35. Sequential therapies for proliferative lupus nephritis.
Contreras G; Pardo V; Leclercq B; Lenz O; Tozman E; O'Nan P; Roth D
N Engl J Med; 2004 Mar; 350(10):971-80. PubMed ID: 14999109
[TBL] [Abstract][Full Text] [Related]
36. DNA topoisomerases: structure, function, and mechanism.
Champoux JJ
Annu Rev Biochem; 2001; 70():369-413. PubMed ID: 11395412
[TBL] [Abstract][Full Text] [Related]
37. Irinotecan in the treatment of colorectal cancer: clinical overview.
Vanhoefer U; Harstrick A; Achterrath W; Cao S; Seeber S; Rustum YM
J Clin Oncol; 2001 Mar; 19(5):1501-18. PubMed ID: 11230497
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and toxicity of irinotecan in patients with colorectal cancer.
Rothenberg ML
Semin Oncol; 1998 Oct; 25(5 Suppl 11):39-46. PubMed ID: 9786315
[TBL] [Abstract][Full Text] [Related]
39. The C-terminal domain but not the tyrosine 723 of human DNA topoisomerase I active site contributes to kinase activity.
Rossi F; Labourier E; Gallouzi IE; Derancourt J; Allemand E; Divita G; Tazi J
Nucleic Acids Res; 1998 Jun; 26(12):2963-70. PubMed ID: 9611242
[TBL] [Abstract][Full Text] [Related]
40. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection.
Morham SG; Kluckman KD; Voulomanos N; Smithies O
Mol Cell Biol; 1996 Dec; 16(12):6804-9. PubMed ID: 8943335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
